For a transgender male patient on testosterone therapy with a ferritin of 12 ng/mL and a borderline low red blood cell count, is it appropriate to start oral iron supplementation?

Iron Replacement in a Transgender Male Patient on Testosterone Therapy

Yes, start oral iron supplementation immediately—ferritin of 12 ng/mL represents clear iron deficiency that warrants treatment, and testosterone therapy increases iron demand through stimulation of erythropoiesis, making iron repletion even more critical in this patient. 1

Why Iron Replacement is Indicated

• A ferritin level below 45 ng/mL in non-inflammatory conditions confirms iron deficiency and warrants treatment. 2
• Your patient's ferritin of 12 ng/mL falls well below this diagnostic threshold, indicating depleted iron stores. 1
• The borderline low RBC count (4.09) suggests early impact on erythropoiesis from iron deficiency. 1

The Testosterone Factor: Why This Patient Needs Iron Even More

Testosterone therapy creates a unique situation that makes iron supplementation particularly important:

• Testosterone stimulates erythropoietin (EPO) production by 21% and increases hematocrit by 7-10%, creating substantially increased iron demand for red blood cell production. 3, 4
• Testosterone suppresses hepcidin by approximately 28%, which increases iron mobilization from stores and enhances iron utilization for erythropoiesis. 3, 4
• Testosterone increases ferroportin expression by 70% and transferrin receptor expression by 43%, both of which accelerate iron turnover and consumption. 3
• This patient started testosterone "a few months ago"—precisely the timeframe when testosterone-induced erythropoiesis peaks and iron stores become depleted. 3, 4
• Without adequate iron supplementation, testosterone-treated patients cannot sustain the increased erythropoiesis and may develop functional iron deficiency despite ongoing testosterone therapy. 4

Critical pitfall to avoid: Do not wait to see if the patient becomes anemic before starting iron—testosterone will continue driving erythropoiesis and further deplete already low iron stores, potentially leading to symptomatic iron deficiency and limiting the hematologic benefits of testosterone therapy. 3, 4

Recommended Iron Supplementation Protocol

First-line therapy:

• Ferrous sulfate 325 mg (65 mg elemental iron) once daily on an empty stomach. 1
• This once-daily regimen optimizes absorption while minimizing gastrointestinal side effects compared to divided dosing. 1

Enhance absorption:

• Co-administer with 80-500 mg vitamin C (ascorbic acid) to increase iron absorption by forming a soluble chelate. 1
• Avoid tea or coffee within one hour of the iron dose, as these inhibit absorption. 5

Treatment duration:

• Continue iron supplementation for approximately 3 months after hemoglobin normalizes to fully replenish marrow iron stores. 1
• In this patient on testosterone, expect ongoing higher iron requirements due to sustained erythropoietic stimulation. 3, 4

Monitoring Strategy

Initial response assessment:

• Check hemoglobin and ferritin at 4 weeks to confirm response to therapy. 1
• Expect hemoglobin to increase by approximately 1 g/dL within 2-4 weeks if responding appropriately. 1, 2

Long-term monitoring:

• After iron stores normalize, monitor blood counts every 3 months for the first year, then every 6 months. 5
• Patients on testosterone therapy may require periodic reassessment of iron status due to ongoing increased iron utilization. 3, 4

Testosterone-specific monitoring:

• The FDA label for testosterone recommends checking hemoglobin and hematocrit periodically to detect polycythemia. 6
• In this patient with low iron stores, the risk of testosterone-induced polycythemia is minimal until iron is repleted, but monitoring remains important once iron stores normalize. 6, 3

Managing Side Effects

• Common gastrointestinal side effects include constipation (12%), diarrhea (8%), and nausea (11%). 1
• If standard ferrous sulfate is not tolerated, consider switching to ferrous gluconate (37-38 mg elemental iron per tablet) or taking the supplement with food, though the latter reduces absorption. 1
• Alternate-day dosing may improve tolerability while maintaining adequate iron absorption. 1, 7

When to Escalate to Intravenous Iron

Consider IV iron if any of the following occur:

• Ferritin fails to improve after 4 weeks of optimized oral therapy. 1
• Patient cannot tolerate oral iron despite formulation changes. 1
• Hemoglobin drops below 10 g/dL. 8
• Evidence of malabsorption (though not applicable in this case). 1

Special Considerations for This Patient Population

• Transgender men on testosterone therapy represent a unique population with increased iron requirements that persist as long as testosterone therapy continues. 3, 4
• Iron deficiency can limit the full hematologic response to testosterone and may contribute to fatigue or reduced exercise capacity. 5, 3
• Proactive iron supplementation in testosterone-treated patients with low ferritin prevents progression to iron deficiency anemia and supports optimal testosterone efficacy. 3, 4